Protara Therapeutics Inc expected to post a loss of 88 cents a share - Earnings Preview

Protara Therapeutics

01/05/2023 18:01

* Protara Therapeutics Inc  TARA.OQ   TARA.O  is expected
to show
no change in quarterly revenue when it reports  results on May 3
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Protara
Therapeutics Inc
is for a loss of 88 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Protara
Therapeutics Inc is $31​, above​ its last closing price
of $3.16. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022              -0.75      -1.55     Missed  -106.7
 Sep. 30 2022  -0.77       -0.76      -0.68     Beat    10.1
 Jun. 30 2022  -1.02       -0.94      -0.80     Beat    14.6​
 Mar. 31 2022  -1.01       -0.90      -0.96     Missed  -6.3
 ​​Dec.                    -0.94      -0.91     Beat    3.5
 31 2021                                                
 Sep. 30 2021  -1.11       -1.01      -0.96     Beat    5​
 Jun. 30 2021  -1.10       -1.05      -1.14     Missed  -8.3
 Mar. 31 2021  -0.73       -0.73      -1.20     Missed  -65.1
 This summary was machine generated May 1 at 17:01 GMT.  All
figures in US dollars  unless otherwise stated